Testing drug sensitivity to guide treatment for colorectal cancer
Vitro 3D Drug Sensitivity Detection of Micro Tumor (PTC) to Guide Postoperative Adjuvant Treatment Strategy and Prognosis Judgment of Colorectal Cancer--Prospective Clinical Study
NA · Peking Union Medical College Hospital · NCT05978349
This study is testing a new 3D drug sensitivity test to see if it can help doctors choose better treatments for people with colorectal cancer after surgery.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, China/Beijing) |
| Trial ID | NCT05978349 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of a 3D drug sensitivity test using micro tumors (PTC) to guide adjuvant therapy decisions for patients with colorectal cancer. Patients aged 18 to 75 who have undergone radical surgery will be randomly assigned to either a group receiving treatment based on the test results or a control group following standard clinical practices. The primary goal is to assess the consistency between the test outcomes and clinical prognosis, ultimately providing real-world data to support personalized treatment approaches for colorectal cancer.
Who should consider this trial
Good fit: Ideal candidates are patients aged 18 to 75 with colorectal cancer who require adjuvant therapy after surgery and have not received prior neoadjuvant treatment.
Not a fit: Patients with metastatic colorectal cancer or those unable to provide tumor samples will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized and effective treatment strategies for colorectal cancer patients, improving their chances of disease-free survival.
How similar studies have performed: While the use of drug sensitivity testing in cancer treatment is gaining traction, this specific approach using 3D micro tumor technology is relatively novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age 18 \~ 75 years old, regardless of gender 2. Patients with colorectal cancer diagnosed by histopathology or cytology 3. Colorectal cancer patients who need adjuvant therapy after radical surgery and have not received neoadjuvant therapy 4. Having at least one assessable tumor focus 5. ECoG physical condition score ≤ 2 points 6. Voluntarily participate and sign informed consent Exclusion Criteria: 1. Patients diagnosed with metastasis 2. Patients who cannot obtain tumor samples 3. Pregnant and lactating women 4. Patients with poor compliance 5. Patients with severe cardiovascular and cerebrovascular complications who cannot receive adjuvant treatment 6. Patients with other malignant tumors 7. Suffering from serious mental and nervous system diseases 8. The researchers believe that patients should not be selected for this study
Where this trial is running
Beijing, China/Beijing
- Peking Union Medical College Hospital, Chinese Academy of Medicine Sciences — Beijing, China/Beijing, China (RECRUITING)
Study contacts
- Study coordinator: Jiaolin Zhou, Professor
- Email: conniezhjl@yahoo.com
- Phone: 13910136704
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Colo-rectal Cancer, colon cancer, rectal cancer, adjuvant therapy, PTC